PD-1 / PD-L1 monoclonal antibody

DRUG5 trials

Conditions

Advanced Breast CancerAdvanced Malignant Solid TumorDiffuse Large B Cell Lymphoma (DLBCL)Gastric / Gastroesophageal Junction AdenocarcinomaNon-Small Cell Lung CancerPrimary Central Nervous System Lymphoma (PCNSL)

Phase 1

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

RecruitingNCT07293754

Repertoire Immune MedicinesAdvanced Malignant Solid Tumor

Start: 2025-12-12End: 2029-04-15Target: 150Updated: 2026-02-17

Phase 2

A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

RecruitingNCT07444437

Suzhou BlueHorse Therapeutics Co., Ltd.Non-Small Cell Lung Cancer

Start: 2026-02-26End: 2028-12-31Target: 45Updated: 2026-05-13

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

RecruitingNCT07523737

Beijing Tongren HospitalDiffuse Large B Cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)

Start: 2026-04-01End: 2028-08-31Target: 43Updated: 2026-04-15

Phase 4

Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

Not yet recruitingNCT07161453

Liaoning Cancer Hospital & InstituteGastric / Gastroesophageal Junction Adenocarcinoma

Start: 2025-09-30End: 2027-12-31Target: 500Updated: 2025-09-08

Unknown Phase

A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer

RecruitingNCT06776861

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdvanced Breast Cancer